A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. by Horvilleur, E et al.
OPEN
ORIGINAL ARTICLE
A role for eukaryotic initiation factor 4B overexpression in the
pathogenesis of diffuse large B-cell lymphoma
E Horvilleur1, T Sbarrato1, K Hill1,5, RV Spriggs1, M Screen1, PJ Goodrem1, K Sawicka1,6, LC Chaplin1, C Touriol2, G Packham3, KN Potter3,
S Dirnhofer4, A Tzankov4, MJS Dyer1, M Bushell1, M MacFarlane1 and AE Willis1
Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the
underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective
upregulation of mRNAs encoding anti-apoptotic and DNA repair proteins. We show that enhanced synthesis of these proteins in
DLBCL is mediated by the relief of repression that is normally imposed by structure in the 50-untranslated regions of their
corresponding mRNAs. This process is driven by signaling through mammalian target of rapamycin, resulting in increased synthesis
of eukaryotic initiation factor (eIF) 4B complex (eIF4B), a known activator of the RNA helicase eIF4A. Reducing eIF4B expression
alone is sufficient to decrease synthesis of proteins associated with enhanced tumor cell survival, namely DAXX, BCL2 and ERCC5.
Importantly, eIF4B-driven expression of these key survival proteins is directly correlated with patient outcome, and eIF4B, DAXX and
ERCC5 are identified as novel prognostic markers for poor survival in DLBCL. Our work provides new insights into the mechanisms
by which the cancer-promoting translational machinery drives lymphomagenesis.
Leukemia (2014) 28, 1092–1102; doi:10.1038/leu.2013.295
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INTRODUCTION
It is well established that altered regulation at the level of mRNA
translation is important in both cancer development and
progression. Rates of protein synthesis are controlled both
globally and specifically, and dysregulation via either route makes
a significant contribution to cell transformation and tumori-
genesis.1–3 In general, global protein synthesis rates are regulated
by the availability of two complexes, the eukaryotic initiation
factor 4F complex (eIF4F) and ternary complex.4
The eIF4F complex comprises eIF4E (the cap binding protein),
eIF4G (a scaffold protein) and eIF4A (a dead box helicase). Two
associated proteins, eIF4B and the functionally related eIF4H,
anchor the complex to the mRNA and increase eIF4A helicase
activity.5,6 Dysregulation of the eIF4F complex members has a
direct role in tumorigenesis,7,8 in part due to increased synthesis
of proteins that are normally poorly translated, particularly those
encoding growth factors and oncogenes.3,4
In diffuse large B-cell lymphoma (DLBCL), the most common
lymphoma subtype, transcriptional profiling has provided impor-
tant insights into lymphoma cell biology and new prognostic
information.9–14 This type of analysis identified three distinct
forms: germinal center B-cell-like DLBCL, activated B-cell-like
DLBCL and type III DLBCL,9,13,14 with a correlation between
expression pattern and patient survival.9,12–14 Recent advances in
treatment have resulted in a significant improvement in outcome
for patients with 5-year survival rates of B55%.15 However, a
significant proportion of patients still succumb to the disease, and
new therapies and prognostic markers to inform treatment
options are required.
As transcriptional changes are not necessarily directly linked to
protein expression,16,17 we have analyzed the translatome of DLBCL
cells. We show that translational dysregulation in DLBCL results in
altered expression of proteins that function in apoptotic processes
and in DNA repair. This results from activation of mammalian target
of rapamycin (mTOR) pathway and increased eIF4B expression,
which overcomes the repressive effects on the translation of
specific mRNAs that is exerted by their highly structured
50-untranslated regions (UTRs). Importantly, we demonstrate that
translational dysregulation of these mRNAs is associated with poor
survival of patients with DLBCL, identifying ERCC5, DAXX and eIF4B
as new prognostic markers for this disease.
MATERIALS AND METHODS
Antibodies
Provenance and dilutions of antibodies are described in Supplementary
Table 1.
Cell culture
All cells were grown in RPMI 1640 with 10–15% fetal calf serum, 5mM
L-glutamine. Cell lines used were GM01953 (control B-cell line), GM03201
(control B-cell line) and five cell lines derived from GC-DLBCL, that is,
DoHH-2 (secondary DLBCL derived from follicular lymphoma (FL)), VAL
(secondary DLBCL derived from FL), SuDHL-6, DB and OCI-LY19. Cell
suspensions from lymph nodes were from the Faculty of Medicine Tissue
Bank, University of Southampton. Approval to use patient tissue was
obtained from the Leicestershire, Northamptonshire and Rutland Research
Ethics Committee (LREC reference 6978).
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Treatments
Inhibitors for mTOR were purchased from Selleck Chemicals (Houston, TX,
USA) for AZD8055 and Sigma Aldrich (St Louis, MO, USA) for PP242. Unless
stated otherwise, treatments were performed with 100 nM AZD8055 or 1 mM
PP242.
SDS-polyacrylamide gel electrophoresis and western blotting
Cell line extracts were prepared as described previously.18 B cells from
lymphomas or tonsils were purified using Miltenyi Biotec (Cologne,
Germany) CD19 beads and MS columns following the supplier’s protocol.
Protein extracts were subjected to electrophoresis on SDS-polyacrylamide
gels. Proteins were detected with the relevant antisera using
chemiluminescent reagents.19
Pulse-labeled immunoprecipitation
For immunoprecipitations, transfected cells were grown at 5 105cells/ml
for 24 h. They were incubated for 6 h in methionine-free medium in the
presence of 0.25mCi of 35S Met-Label (Hartmann Analytics, GmbH,
Braunschweig, Germany). Cells were then lysed, and immunoprecipitation
was done using protein A/G agarose beads (Santa Cruz Biotechnology,
Dallas, TX, USA). Immunoprecipitated proteins were boiled in SDS
containing buffer and were subjected to electrophoresis before Coomassie
staining and autoradiography were done.
Sucrose density-gradient centrifugation and RNA detection
Sucrose density-gradient centrifugation was used to separate ribosomes
into polysomal and subpolysomal forms. Gradients were then fractionated
with continuous monitoring at 254 nm and RNA was isolated from each
fraction as described previously.20
RNA analysis
Northern analysis of RNA isolated from sucrose density gradients was
performed as described previously20 on at least three independent
occasions.
Reverse transcriptase-PCR and quantitative reverse transcriptase-PCR
were performed as described previously.21
Preparation of fluorescently labeled cDNA for microarray
hybridization and data analysis
Human cDNA microarrays were used as described previously.20
Fluorescently labeled DNA probes were generated from equal
proportions of RNAs (B7 mg) of pooled non-polysomal fractions
(fractions 1–4, Cy3) and pooled polysomal fractions (fractions 6–11, Cy5).
Microarray slides were scanned using a GenePix 4200A microarray scanner
and GenePix Pro 5.1 software (Axon Instruments, Union City, CA, USA).
Analysis of microarray data
GenePix Pro 5.1 was used to quantify fluorescence intensities for individual
spots on the microarray. The data were processed in the R platform using
the Limma package.22,23 The resulting log2-transformed ratios were as
follows:
Mi (gene x)¼ Log2[Cy5(polysomal-associated mRNA)/Cy3(non-polyso-
mal mRNA)]; (i replicates of experiment, i¼ 1:3)
The log2-transformed ratios of polysomal over subpolysomal signal for
each condition were then analysed by a non-parametric ranking approach
using the RankProd package.24,25 mRNAs were clustered using Gene
Ontology annotations through DAVID (david.abcc.ncifcrf.gov) and IPA
(Ingenuity Systems, www.ingenuity.com); pie charts were created in
Microsoft Excel and heatmaps were created using MultiExperiment
Viewer MeV (http://www.tm4.org/mev.html).
Death receptor-induced apoptosis
Cells were grown to 1 106 cells/ml and treated with different
concentrations of His-tagged TRAIL (tumor necrosis factor-related
apoptosis-inducing ligand) or anti-FAS antibody. Cells were collected at
4 h post treatment and stained for Annexin V and propidium iodide, and
then analysed by flow cytometry.
Tissue microarrays
The two different tissue microarrays have been described previously.26 The
immunostaining was performed with histostainR plus bulk kit (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s instructions. eIF4B staining
showed a presence/absence pattern that was determined for each tumor.
As expression changes were more gradual for the other proteins, tissue
arrays were scored using the immunoreactive score method.27 Scoring was
carried out on two independent occasions. The population was then
divided into two groups using median staining intensity in the DLBCL
population as a threshold. The survival of these populations was plotted
using the R package ‘a package for survival analysis’28 and significance of
the changes was assessed by Cox regression.
Plasmids and siRNA
50-UTRs of ERCC5, BCL2 and DAXX were amplified by PCR (pfu DNA
polymerase) and subcloned between the Spe1 and Nco1 restriction sites of
a pGL3 vector. The pSV-RL vector expressing Renilla luciferase was used as
an internal control. The Renilla vectors with different 50-UTR sizes are
described in Supplementary Table 2. In this case, pGL3 was used as an
internal control.
eIF4B small interfering RNA (siRNA) and non-targeting control were
provided as a SMART-pool of target plus siRNA (Dharmacon, Thermo Fisher
Scientific, Waltham, MA, USA).
Transfection
Transfections were performed using a Nucleofector 2b TM (Lonza, Basel
Switzerland), according to the manufacturer’s instructions. All cell lines
were transfected in the solution L using the following programs: GM01953
C-009, DoHH-2A-020 and OCI-LY19 M-013. For each transfection of 2 106
cells, 100 pmol of siRNA were used. For luciferase assays, 1 mg of reporter
pGL3 vector and 0.3mg of pSV-RL were added.
UTR analysis
The sequences of the 50-UTRs were analysed for upstream open reading
frames, potential internal ribosome entry segment and terminal oligo-
pyrimidine tract motifs (in-house Perl scripts). MicroRNA target sites were
predicted using TargetScan (www.targetscan.org), using conserved targets
of conserved microRNA families. Structures were predicted using
RNAfold.29
RESULTS
cDNA microarray analysis shows that a subset of mRNAs are
subject to differential translational regulation in DLBCL
To identify selective changes in the translatome in DLBCL,
polysome profiling was carried out. Cytoplasmic extracts prepared
from five DLBCL cell lines (VAL, DoHH-2, SuDHL-6, OCI-LY19 and
DB) and two control B-cell lines (GM03201, GM01953) derived
from disease-free individuals were separated on 10–60% sucrose
gradients (Supplementary Figure 1) and the RNA isolated. RNA
derived from fractions 6–10 (polysomes) was compared with RNA
from fractions 1–4 (subpolysomes) on microarrays to identify
candidate mRNAs whose translational behavior differs significantly
from the translation pattern observed in the control cells. These
transcripts were then classified into different categories based on
their biological function (Figure 1, Supplementary Figure 2).
In DLBCL cell lines, mRNAs encoding anti-apoptotic proteins,
transcription factors, proteins required for cell migration, DNA
repair enzymes and subsets of RNA-binding proteins, including
eIF4B (Figure 1, Supplementary Figure 2), were translationally
upregulated. In contrast, mRNAs encoding pro-apoptotic proteins,
cell signaling and a different subset of RNA-binding proteins were
translationally downregulated (Figure 1a).
Changes in gene expression and the synthesis of specific proteins
in DLBCL validate cDNA microarray analysis
To assess the changes in expression of proteins that are associated
with tumorigenesis, mRNAs whose protein products are involved
in apoptosis and DNA repair were studied. Cell lysates were
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separated by SDS-polyacrylamide gel electrophoresis and
immunoblotted for the proteins shown (Figures 2a and b,
Supplementary Table 3). Differences in expression were observed
in all cases, in agreement with the profiling data (Figure 1 and
Supplementary Figure 2). For proteins that function in apoptosis,
the data show that TRADD (tumor necrosis factor receptor type
1-associated death domain protein) and FAS were downregulated,
whereas DAXX, BCL2, TRAIP and c-Myc were upregulated, albeit to
different extents (Figure 2a(i)). There were no corresponding
changes in the total amount of mRNA present (Figure 2a(ii),
Supplementary Figure 3). For example, the level of TRADD mRNA
was similar in the control cell lines and the DLBCL cell lines, and
although FAS mRNA levels were more variable, neither of these
correlated with the expression of the protein. The cell lines used in
the study carry the t(14:18) translocation that couples the
immunoglobulin heavy chain locus to the BCL2 gene resulting in
transcriptional upregulation of BCL2 mRNA.30 As expected, the
levels of BCL2 mRNA were higher in four out of five of the
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Figure 1. mRNAs involved in apoptosis and DNA damage response that displayed significantly different ranking in DLBCL lines compared with
control cells. (a) Pie charts showing the functional distribution of proteins whose mRNA is (i) more or (ii) less polysome-associated in DLBCL
cells compared with control. (b and c) A color scale was used to represent the ratio of mRNA in subpolysome to polysome fractions.
Transformed from the log2[polysome:subpolysome], where blue indicates subpolysome-associated and yellow signifies that the mRNA is
predominantly polysome-associated. (b(i)) mRNAs associated with apoptotic processes that are translationally upregulated. Av control
represents the average value for the GM03201 and GM01953 cell lines, av DLBCL the average value for VAL, DoHH-2, Sud-HL6, OCI-LY19 and
DB cell lines. (b(ii)) mRNAs associated with apoptotic processes that are translationally downregulated. (c(i) mRNAs associated with DNA repair
processes that are translationally upregulated. (c(ii)) mRNAs associated with DNA repair processes that are translationally downregulated.
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DLBCL-derived cell lines. However, this change was insufficient to
account for the large increase in observed protein levels in some
of the lymphoma cell lines. The differential expression of
these apoptotic proteins was shown to affect cell sensitivity to
FAS-mediated apoptosis (Supplementary Figure 4).
The translational profiling data also suggested that there would
be differences in the synthesis of proteins that function in DNA
repair. Therefore, western analysis was performed to examine the
expression of ERCC5, BRCA2 and MNAT1 (Figure 2b(i),
Supplementary Table 3). The levels of these proteins were
increased with no corresponding changes in the levels of the
mRNA, again strongly suggesting translational dysregulation
(Figure 2b(ii), Supplementary Figure 3). Importantly, dysregulated
expression of these proteins has not been reported previously in
DLBCL.
Western blot analysis was carried out on patient tumor samples
to examine the levels of BCL2, DAXX and ERCC5 (Figure 2c). The
data show that similar changes also occur in patient samples with
increased expression of these proteins detected when compared
with B cells derived from control tonsils.
mRNAs with highly structured 50-UTRs are translationally
upregulated in DLBCL
The enhanced translation of subsets of mRNAs in DLBCL could be
due to unique RNA elements, as the majority of mammalian
mRNAs contain regulatory RNA motifs, including upstream open
reading frames, internal ribosome entry segments, terminal
oligopyrimidine tracts and microRNA-binding sites.31 Therefore,
the UTRs of the mRNAs in the ‘up’ and ‘down’ lists were examined
to assess whether there were unique features that could
contribute to their up- or downregulation. The proportion of
mRNAs containing internal ribosome entry segments, upstream
open reading frames, terminal oligopyrimidine tracts or microRNA
target sites remained unchanged between the gene lists and the
whole array (Supplementary Figure 5A). However, the data show a
significant increase in the average 50-UTR length and in the
predicted minimum free energy (DG) of folding in the list of genes
that were translationally upregulated in DLBCL, compared with
the complete array (Figures 3a(i and ii)). Further examination of
the 50-UTR length (Supplementary Figure 5B) reveals that the
cumulative distribution corresponding to the translationally
upregulated group is shifted towards the longer lengths
compared with the downregulated and unchanged groups; the
DG data shows a similar pattern with a shift towards more
negative free energies in the translationally upregulated group
(Supplementary Figure 5C(i)). These data suggest that a popula-
tion of mRNAs with long and/or structured 50-UTRs is enriched in
the translationally upregulated group.
To determine whether the higher overall DG observed in the
translationally upregulated mRNAs was simply a consequence of
the longer 50-UTR lengths, a number of criteria were examined,
including the distributions of the number of nucleotides that were
either paired (Supplementary Figure 5C(ii)) or free (Supplementary
Figure 5C(iii)), and the longest string of nucleotides involved in a
structure (Supplementary Figure 5C(iv)) or unstructured regions
(Supplementary Figure 5C(v)). These analyses show that there is a
significant enrichment of mRNAs containing structure in transla-
tionally upregulated mRNAs in DLBCL, whereas the number of free
nucleotides and the size of unstructured regions is similar in all
three groups. Taken together, these data suggest that the degree
of structure is more important than length in determining
enrichment in the ‘up’ list.
To investigate this finding further, the 50-UTRs of three of the
mRNAs that were shown to be translationally upregulated (ERCC5,
BCL2 and DAXX) were subcloned into luciferase reporter vectors
(Figure 3b(i)) and transfected into DLBCL-derived cell lines
(Figure 3b(ii)). There was an increase in the synthesis of the
luciferase reporter enzyme from all constructs in the DLBCL-
derived cell lines when compared with the control, suggesting
that enhanced translation of those mRNA in DLBCL was
dependent upon features in their 50-UTRs. Therefore, vector
constructs were generated to examine the effect of length/
structure on reporter protein synthesis in DLBCL (Figure 3c(i),
Supplementary Table 2). These constructs were transfected into
the control and DLBCL-derived cell lines and luciferase expression
was determined. The data show that constructs with longer
50-UTRs were repressed in the control cells, and that this repression
is significantly less in DLBCL cell lines (Figure 3c(ii)). It has been
shown in other systems that modifying the protein components
of the translation apparatus has the net effect of altering the
dynamic range of translation efficiencies across the entire
transcriptome, so that those mRNAs that are normally poorly
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Figure 2. mRNAs identified by the translational profiling show
differential protein expression. (a(i) and b(i)) Protein extracts were
generated from DLBCL cell lines or from control B cells (GM03201
and GM01953). These were subjected to SDS-polyacrylamide gel
electrophoresis (PAGE), immunoblotted and probed with the
antibodies indicated to assess differences in expression in the
proteins from genes with a role in apoptosis (a) or DNA repair
processes (b). (a(ii) and b(ii)) To measure total RNA levels, samples
were taken and RNA was extracted. These samples were subjected
to northern analysis using probes against DAXX, BCL2, FAS and MYC,
or reverse transcriptase-PCR using primers against TRAIP, ERCC5,
CCNH, BRCA2, MNAT1, actin and tubulin. Actin/tubulin were used as
loading controls. The data show that there is a large increase in the
expression of a number of proteins that function in apoptotic and
DNA repair pathways with no net change in mRNA levels, in
agreement with the array data. (c) B cells were purified from tumors
obtained from individuals with DLBCL or from tonsils. Cell extracts
were generated and samples separated by SDS-PAGE and immuno-
blotted with the antibodies shown. The data show that there is
increased expression of DAXX, ERCC5 and BCL2 in patient samples
in agreement with the cell line and the translational profiling data.
Dysregulation of translation in DLBCL
E Horvilleur et al
1095
& 2014 Macmillan Publishers Limited Leukemia (2014) 1092 – 1102
translated, for example, those that contain highly structured
50-UTRs as shown here, are selectively upregulated.4,32 Therefore,
the levels and phosphorylation status of the translational
apparatus in DLBCL were assessed (Figure 3d). Interestingly, the
data show that whereas there was no difference in the expression
of the eIFs that have been shown previously to be associated with
a transformed phenotype, namely eIF4E, eIF4G and eIF4A,3,33
there was an increase in the expression of eIF4B and a relative
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Figure 3. mRNAs containing highly structured 50-UTRs are preferentially translated in DLBCL. (a) The cDNA microarray data were analysed and
the average 50-UTR lengths, and DG values were calculated for those mRNAs in the ‘up’ and ‘down’ lists, and the significance of the difference
to the whole array was assessed by Student’s t-tests. The data show that the mRNAs in the upregulated list have longer 50-UTRs (P¼ 0.002; i),
have greater DG values (P¼ 0.001; ii) and have more nucleotides incorporated into hairpins (P¼ 0.006; iii); all three criteria would be
expected to decrease the translatability of mRNAs in these groups. (b(i)) The cDNAs corresponding to the 50-UTRs of DAXX, ERCC5 and BCL2
were subcloned into a luciferase reporter vector based on pGL3. (b(ii)) The reporter constructs were transfected into cell lines derived from
DLBCL and control B cell, and luciferase activity determined. The data show that there is greater expression of luciferase in the DLBCL-derived
cell lines than in the control cell lines for all plasmids, suggesting that the 50-UTRs are less inhibitory in these cell lines. Significance was
assessed by paired Student’s t-tests on three independent experiments (*Po0.05, **Po0.01 and ***Po0.001). (c(i)) Unrelated DNA sequences
of increasing length (Supplementary Table 2) were subcloned into the 50-UTR of pGL3 upstream of the luciferase cistron. (c(ii)) These plasmids
were transfected into the control cell line (GM01953) and cell line derived from DLBCL (DoHH-2, OCI-LY19 and DB), and luciferase activity
determined. (d) Protein extracts derived from cell lines representative of either DLBCL (Val, DoHH-2, SuDHL-6, OCI-LY19 and DB) and two
control B-cell lines (GM03201 and GM01953) were separated by SDS-polyacrylamide gel electrophoresis (PAGE). Samples were immunoblotted
with eukaryotic initiation factor (eIFs)-specific antibodies. The data show that only eIF4B levels were increased in these cell lines. (e(i)) Extracts
were generated from B cells purified from tonsils of tumor-free individuals or tumors from patients with DLBCL, and separated by SDS-PAGE
and immunoblotted to examine eIF4B levels. Tubulin was used as a loading control. The data show that eIF4B levels were elevated in the five
DLBCL samples tested. (e(ii)) Tissue microarrays that contained tissues from 362 lymphomas, including 196 DLBCL, 76 FL and 52 chronic
lymphocytic leukemias (CLLs) were probed by an antibody against eIF4B and scored as described in the experimental procedures section.
These data show that there is significantly higher expression of eIF4B in DLBCL compared with that in CLL and FL. Significance between the
different categories was assessed by w2-test (*Po0.05).
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increase in eIF4B-P (Figure 3d). eIF4B stimulates translation by
increasing the activity of the helicase eIF4A,34 it is required for 48S
complex formation via its interaction with poly(A)-binding protein
and contributes to selective translation of mRNAs with highly
structured 50-UTRs.3,5,35 Importantly, eIF4B expression was also
increased in DLBCL patient samples, albeit to differing extents
(Figure 3e(i)). To analyze eIF4B expression from a larger number of
patient samples simultaneously, tissue microarrays were used
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Figure 4. eIF4B modulation restores repression of translation on mRNAs that is exerted by structured 50-UTRs. (a) Cell lines derived from
patients with DLBCL (DoHH-2 and OCI-LY19) and control B cells (GM01953) were transfected with siRNA to eIF4B. After 48 h, cell extracts were
generated, which were separated by SDS-polyacrylamide gel electrophoresis and immunoblotted for eIF4B and ERCC5 levels. Pulse-labeled
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(GM01953) or cell lines derived from DLBCL (DoHH-2, OCI-LY19 and DB) ±siRNA to eIF4B, and luciferase activity determined.
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(Supplementary Figure 6A, Supplementary Table 4). These
contained tissues from 362 lymphomas, including 196 DLBCL, 76
FLs and 52 chronic lymphocytic leukemias. In agreement with the
cell line data, there was a significant increase in eIF4B expression
in the DLBCL tumors compared with chronic lymphocytic
leukemia and FL (Figure 3e(ii)). Interestingly, there was a
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correlation between eIF4B overexpression and the levels of DAXX
and ERCC5 in the tumor samples (Figure 2c) and in tissue
microarrays (Supplementary Figure 6B).
Translational dysregulation of ERCC5, DAXX and BCL2 correlates
with enhanced eIF4B expression
To test the hypothesis that increased eIF4B levels directly elevated
the synthesis of subsets of proteins, including DAXX and BCL2 in
DLBCL, cells were transfected with siRNA directed against eIF4B
mRNA and potential target proteins were analyzed, either by
western blotting (ERCC5) or pulse-labeling and immunoprecipita-
tion (BCL2 and DAXX, due to the long half-lives of these proteins,
which would mask changes in net synthesis rates). When eIF4B
levels were reduced, there was a decrease in the expression of
ERCC5, BCL2 and DAXX (Figure 4a).
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Figure 6. Tissue microarray shows that altered expression of the
proteins identified by translational profiling in tumors from patients
with B-cell lymphoma corresponds with survival. (a) Tissue micro-
arrays that contained tissues from 362 lymphomas, including 196
DLBCL, 76 FL and 52 chronic lymphocytic leukemias (CLLs) were
probed with antibodies against ERCC5 (i) and DAXX (ii), and scored
as described in the experimental procedures section. The graphs
represent percentage of tumors from each type expressing high
levels of the scored protein. The data show that there are differences
in expression of DAXX in the DLBCL patient samples compared with
the other tumor types, and for ERCC5 a difference in the expression
in FL and DLBCL when compared with CLL. Significance between
the different categories was assessed by w2-test (*Po0.05, **Po0.01,
***Po0.001). (b) Patients were separated into groups that have low
or high expression of ERCC5 (i) or DAXX (ii), or eIF4B (iii). Survival
curves were generated using Kaplan–Meier approximation to
compare overall survival in different groups of patients. The
significance of the changes in survival was assessed using log-rank
P-value. The data show that there are significant decreases in
survival in patients that have high expression for ERCC5 (P¼ 0.044),
DAXX (P¼ 0.003) and eIF4B (P¼ 0.0081).
Figure 7. A schematic diagram to represent the changes in DLBCL
that occur as a consequence of eIF4B overexpression. Taken
together, the data suggest a model wherein increased signaling
through mTOR in DLBCL increases the expression of eIF4B, which
drives the translation of mRNAs that contain highly structured
50-UTRs and lead to the upregulated synthesis of ERCC5, DAXX and
BCL2. Increased expression of these proteins negatively impacts
upon patient survival, providing three new prognostic markers for
this disease: eIF4B, DAXX and ERCC5.
Figure 5. Signaling through mTOR links eIF4B expression to DAXX and ERCC5. (a(i)) Cell lines derived from DLBCL or control cells, as shown,
were lysed, separated by SDS-polyacrylamide gel electrophoresis (PAGE), and immunoblottings were probed with antibodies against
phosphoinositide 3-kinase (PI3K), protein kinase B (PKB), mTOR and 4EBP1. The data suggest that the mTOR signaling pathway is upregulated
in these cells when compared with that in the controls. (a(ii)) Schematic to illustrate signaling through the mTOR pathway. (b and c) Two
DLBCL cell lines DoHH-2 (b) and OCI-LY19 (c) were treated with the mTOR inhibitor AZD8055 at 25 or 100 nM. After 2 h, cells were collected and
post-nuclear fractions were applied to sucrose density gradients to separate the actively translating polysomes from the subpolysomal
material (b(i) and c(i)). RNA was isolated from each fraction and quantitative reverse transcriptase-PCR was used to assess the proportion of
RPS16 (b(ii) and c(ii)), eIF4B (b(iii) and c(iii)) and eIF4A (b(iv) and c(iv)) associated with each fraction. (d) Control cell line (GM01953) or DLBCL
lines (DoHH-2 and OCI-LY19) were treated with PP242 or AZD8055, cell extracts were generated, separated by SDS-PAGE and immunoblotted
for 4EBP1-P, eIF4B, eIF4B-P, ERCC5 and DAXX. The data show that the reduction in eIF4B as a result of exposure to mTOR inhibitors also reduces
the expression of its downstream targets ERCC5 and DAXX.
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To examine whether the regulation eIF4B target mRNAs was
mediated by elements in their 50-UTRs, the level of eIF4B was
reduced by siRNA (Figure 4b(i)) and cells were transfected with
reporter plasmids (Figure 4b(ii–v)). There were decreases in the
expression of luciferase from the reporter plasmids that contained
the ERCC5, BCL2 and DAXX 50-UTRs in the lymphoma-derived cell
lines when eIF4B was reduced (Figure 4b(iii–v)). These data
suggest that high eIF4B levels could contribute to the enhanced
synthesis of subsets of proteins, including DAXX, BCL2 and ERCC5,
by unwinding structured 50-UTRs. To confirm that the relief of
repression on structured mRNAs was directly due to the higher
levels of eIF4B in these cells and independent of sequence, cells
were co-transfected with siRNAs against eIF4B and constructs
containing structured 50-UTRs of unrelated sequence
(Supplementary Table 2). In this case, the enhanced synthesis
that was observed in DLBCL-derived cells when compared with
the control lines was ablated (Figure 4c).
Signaling via the mTOR signaling pathway upregulates eIF4B
expression
The profiling data (Figure 1, Supplementary Figure 2) indicated
that eIF4B was also dysregulated in DLBCL at the level of
translation. Several lines of evidence suggest that the translational
dysregulation of eIF4B could result from aberrant signaling
through the mTOR pathway. Activation of the mTOR pathway
has been shown previously in DLBCL, although not in the cell lines
used herein, and a recent study has also reported activation of
mTOR in a subset of DLCBL patients.36 Moreover, eIF4B was
present on two lists of genes whose expression changed following
mTOR inhibition.37,38 Therefore, DLBCL and control cells were
immunoblotted to assess the expression and phosphorylation
status of protein kinase B/AKT, mTOR and 4EBP1. There was an
increase in expression and phosphorylation of these proteins in
the DLBCL-derived cell lines (Figure 5a). Although mTOR activation
induces phosphorylation of eIF4B,35 our data show that there are
changes in the total level of eIF4B protein in DLBCL. To assess
whether mTOR inhibition decreased the translation of eIF4B in
DLBCL, cells were incubated with the inhibitor AZD8055.
Polysomes were separated by sucrose density-gradient
centrifugation, and quantitative reverse transcriptase-PCR was
carried out to assess changes in polysomal distribution of mRNAs
encoding a known mTOR target, RPS16 and eIF4B (Figures 5b(i–iv)
and c(i–iv)). eIF4A was used as a control. The data showed a shift
of RPS16 and eIF4B mRNAs from the polysomes following
incubation with AZD8055 (Figures 5b(ii, iii) and c(ii, ciii)), but little
or no effect on eIF4A mRNA (Figures 5b(iv) and c(iv)), which again
suggests that eIF4B expression is regulated via signaling through
mTOR.37,38
To assess the effect of mTOR inhibitors PP242 and AZD8055 on
eIF4B protein levels, cells were incubated with these compounds
and immunoblottings carried out. As expected, there were
changes in the degree of phosphorylation of 4EBP1 and eIF4B35
but, importantly, also a decrease in expression of eIF4B, and two of
its downstream targets, ERCC5 and DAXX, albeit to different
extents (Figure 5d).
Differences in eIF4B, ERCC5 and DAXX expression in cell lines
correlate with alterations in B-cell lymphoma tumor samples and
patient survival
It was then important to assess whether the differences in protein
expression were also present in patients with DLBCL and whether
this was associated with patient survival. It is well established that
BCL2 is upregulated in different non-Hodgkin lymphoma types,39–41
and its elevated expression is associated with poor prognosis in
DLBCL;41 hence, the role of this protein in patient survival was not
examined further. However, DAXX and ERCC5 expression have not
been studied previously in DLBCL in this regard. Therefore, to
determine the expression of DAXX and ERCC5 in a large number
of patient samples simultaneously, tissue microarrays were used
(Supplementary Figure 6, Supplementary Table 4). ERCC5 expres-
sion was significantly higher in DLBCL when compared with that
in chronic lymphocytic leukemia (Figure 6a(i)). DAXX protein
expression in DLBCL was increased significantly when compared
with that in FL and chronic lymphocytic leukemia (Figure 6a(ii)).
Kaplan–Meier analysis was performed to determine whether there
were differences in survival associated with the increased
expression of DAXX, ERCC5 and eIF4B (Figures 6b(i–iii)).
Importantly, the data show that high DAXX, ERCC5 and eIF4B
expression correlated with poor overall survival for all subtypes of
DLBCL, providing three new prognostic markers that would identify
those with worse outcome for this disease (Figures 6b(i–iii)).
DISCUSSION
Our data allow us to propose a model whereby aberrant signaling
through mTOR leads to an upregulation in eIF4B, which directly
drives the translation of a subset of mRNAs that contain structured
50-UTRs, including those involved in tumorigenesis and chemo-
resistance, such as DAXX, BCL2 and ERCC5 (Figure 7). Importantly,
we identified eIF4B and two of its targets, DAXX and ERCC5, as
markers of poor prognosis in DLBCL, suggesting that the increased
expression and activation of this protein drives tumorigenesis
(Figures 4, 6 and 7).
The data indicate that the increase in eIF4B expression occurs at
the level of translation (Supplementary Figure 3 and Figure 5) and,
in agreement with previous data,38 that this is downstream of
mTOR signaling (Figures 5 and 7). It has been suggested that
although signaling through mTORC1 is required for the selective
upregulation of terminal oligopyrimidine tract containing mRNAs,
this pathway does not directly control the translation of mRNAs
with long and/or structured 50-UTRs.38 However, we show that in
DLBCL, upregulation of eIF4B levels by the mTOR pathway
increases the translation of selected mRNAs that contain
structured 50-UTRs (Figures 4, 5 and 7). Our data are supported
by studies, which show that silencing of eIF4B in HeLa cells
reduces the translation of selected mRNAs that contain structured
50-UTRs.35
We demonstrate that high DAXX expression correlated with
poor patient survival (Figure 6). The cellular role of DAXX is
complex, with opposing effects being attributed for DAXX in
tumor necrosis factor and FAS signaling to apoptosis.42–44
In addition, mutations that inactivate DAXX function are associated
with prolonged survival of patients with pancreatic cancer.45
It is well established that increased expression of BCL2 is
associated with DLBCL and it has been shown previously that high
expression of BCL2 is associated with poor survival,46,47
particularly for germinal center B-cell-like such as DLBCL.47 The
data presented here suggest that increased translation of BCL2
also contributes to the elevated levels of this protein in DLBCL
(Figures 1, 2 and 6). Similarly, we show that ERCC5 expression is
increased in DLBCL (Figures 1, 2 and 6). ERCC5 is an essential
component of the nucleotide excision repair pathway that is used
to repair damaged DNA following exposure to therapeutic agents
such as cisplatin.48 In addition, it has been shown recently that
eIF4B is present as part of a gene expression signature of acquired
resistance to cisplatin in patients with gastric cancer.49 Inhibition
of these DNA repair pathways, as part of combination therapy
with mTOR inhibitors, could therefore provide alternative
treatment options for patients with DLBCL that respond poorly
to conventional therapy.48 In this regard, a recent trial has been
established to evaluate mTOR inhibitors for the treatment of
patients with relapsed or refractory DLBCL.50
In summary, our data show that increased eIF4B expression
makes a significant contribution to the development of tumori-
genesis in DLBCL. Targeting the proteins that are translationally
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upregulated and which have not been previously identified as
associated with this disease, for example, DAXX or ERCC5, in
addition to direct methods to reduce eIF4B expression or activity,
could provide new therapeutic options, particularly for patients
who do not respond to conventional treatment.
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